
GEMINI-NSCLC: NSCLC Biomarker Study
Non-Small Cell Lung CancerNon-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance.

DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
Non Small Cell Lung CancerSmall-cell Lung CancerObservational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey

Meaning of Recovery After Lung Cancer Surgery
RecoveryLung Cancer1 moreThe purpose of this study is to find out the meaning of recovery after lung cancer surgery from a patient's point of view. The results of this study would help improve postoperative recovery in lung cancer patients.

Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Non Small Cell Lung CancerMolecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.

To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer
Lung CancerThis topic to take large multicenter study real world, the advanced liquid biopsy will ctDNA methylation detection technique is applied to pulmonary nodules differential diagnosis and early lung cancer screening, validation of early lung cancer screening and diagnosis of molecular classification system model, the feasibility of the development of early lung cancer screening and diagnosis of molecular classification system, improve its early screening early detection accuracy and efficiency, Improve the survival status of lung cancer high-risk population. At the same time, this project combined AI analysis technology of LDCT image results with ctDNA methylation detection, so as to overcome false negatives caused by the deficiency of ctDNA methylation detection technology in sensitivity, specificity, stability and flux, and correct false positive results that may be caused by AI analysis technology of LDCT image results. The combination of the two can avoid missed diagnosis and over - examination and over - treatment.

Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests-...
NeoplasmColorectal6 moreThe purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.

Understanding Rural Patient and Provide Preferences for Mobile Lung Cancer Screening Clinics
Lung CancerThe purpose of this study is to research patient preferences for lung cancer screening and pilot mobile units to address the barrier of access that decreases participation in lung cancer screening.

Mass Spectral Fingerprinting in Lung Cancer
Lung CancerTo answer the question whether a disease specific profile of breath in patients with lung cancer can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
Lung NeoplasmsThe mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.

Detection of Genetic Markers of Lung Cancer
Lung CancerThe purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.